232 related articles for article (PubMed ID: 25392022)
1. Isotretinoin exposure during pregnancy: a population-based study in The Netherlands.
Zomerdijk IM; Ruiter R; Houweling LM; Herings RM; Sturkenboom MC; Straus SM; Stricker BH
BMJ Open; 2014 Nov; 4(11):e005602. PubMed ID: 25392022
[TBL] [Abstract][Full Text] [Related]
2. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.
Schaefer C; Meister R; Weber-Schoendorfer C
Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462
[TBL] [Abstract][Full Text] [Related]
3. Fetal exposure to isotretinoin-an international problem.
Garcia-Bournissen F; Tsur L; Goldstein LH; Staroselsky A; Avner M; Asrar F; Berkovitch M; Straface G; Koren G; De Santis M
Reprod Toxicol; 2008 Jan; 25(1):124-8. PubMed ID: 18077132
[TBL] [Abstract][Full Text] [Related]
4. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review.
Crijns HJ; Straus SM; Gispen-de Wied C; de Jong-van den Berg LT
Br J Dermatol; 2011 Feb; 164(2):238-44. PubMed ID: 20716214
[TBL] [Abstract][Full Text] [Related]
5. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective.
Bérard A; Azoulay L; Koren G; Blais L; Perreault S; Oraichi D
Br J Clin Pharmacol; 2007 Feb; 63(2):196-205. PubMed ID: 17214828
[TBL] [Abstract][Full Text] [Related]
6. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S
J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419
[TBL] [Abstract][Full Text] [Related]
7. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.
Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH
Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863
[TBL] [Abstract][Full Text] [Related]
8. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328
[TBL] [Abstract][Full Text] [Related]
9. Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies.
Crijns I; Straus S; Luteijn M; Gispen-de Wied C; Raine J; de Jong-van den Berg L
Drug Saf; 2012 Jan; 35(1):27-32. PubMed ID: 22050373
[TBL] [Abstract][Full Text] [Related]
10. Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study.
Crijns I; Mantel-Teeuwisse A; Bloemberg R; Pinas E; Straus S; de Jong-van den Berg L
Expert Opin Drug Saf; 2013 Jan; 12(1):29-38. PubMed ID: 23163396
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of isotretinoin exposure during pregnancy.
Dai WS; LaBraico JM; Stern RS
J Am Acad Dermatol; 1992 Apr; 26(4):599-606. PubMed ID: 1597546
[TBL] [Abstract][Full Text] [Related]
12. Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France.
Autret-Leca E; Kreft-Jais C; Elefant E; Cissoko H; Darrouzain F; Grimaldi-Bensouda L; Attia S; Jonville-Béra AP
Drug Saf; 2010 Aug; 33(8):659-65. PubMed ID: 20635824
[TBL] [Abstract][Full Text] [Related]
13. A pregnancy-prevention program in women of childbearing age receiving isotretinoin.
Mitchell AA; Van Bennekom CM; Louik C
N Engl J Med; 1995 Jul; 333(2):101-6. PubMed ID: 7777014
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcomes and factors associated with voluntary pregnancy termination in women who had been treated for acne with isotretinoin.
Yook JH; Han JY; Choi JS; Ahn HK; Lee SW; Kim MY; Ryu HM; Nava-Ocampo AA
Clin Toxicol (Phila); 2012 Dec; 50(10):896-901. PubMed ID: 23116253
[TBL] [Abstract][Full Text] [Related]
15. Women's experiences with isotretinoin risk reduction counseling.
Werner CA; Papic MJ; Ferris LK; Lee JK; Borrero S; Prevost N; Schwarz EB
JAMA Dermatol; 2014 Apr; 150(4):366-71. PubMed ID: 24258663
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study.
Chi CC; Wang SH; Mayon-White R; Wojnarowska F
JAMA Dermatol; 2013 Nov; 149(11):1274-80. PubMed ID: 24005903
[TBL] [Abstract][Full Text] [Related]
17. Face-to-face: isotretinoin use and pregnancy outcome.
Tırmıkçıoğlu Z; Tatlıparmak A
Int J Dermatol; 2024 Feb; 63(2):232-238. PubMed ID: 38095245
[TBL] [Abstract][Full Text] [Related]
18. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
Kovitwanichkanont T; Driscoll T
Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
[TBL] [Abstract][Full Text] [Related]
19. Isotretinoin: Still the cause of anxiety for teratogenicity.
Altıntaş Aykan D; Ergün Y
Dermatol Ther; 2020 Jan; 33(1):e13192. PubMed ID: 31837244
[TBL] [Abstract][Full Text] [Related]
20. Promoting safe use of isotretinoin by increasing contraceptive knowledge.
Werner CA; Papic MJ; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Apr; 151(4):389-93. PubMed ID: 25650743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
